What is the most effective weight loss peptide in 2026?

Based on clinical trial data, retatrutide is the most effective weight loss peptide ever tested, achieving 28.3% average body weight loss (up to 30.3%) in the TRIUMPH-1 trial. However, it is not yet FDA-approved. Among approved medications, tirzepatide (Mounjaro/Zepbound) is the most effective at 22.5% average weight loss.

Is Mounjaro better than Ozempic for weight loss?

Yes, clinical trial data consistently shows tirzepatide (Mounjaro/Zepbound) produces greater weight loss than semaglutide (Ozempic/Wegovy). SURMOUNT-1 showed 22.5% body weight loss on tirzepatide 15mg vs 14.9% on semaglutide 2.4mg in STEP-1. Tirzepatide targets two receptors (GLP-1 + GIP) while semaglutide targets only GLP-1.

Is there a weight loss pill that works like Ozempic?

Yes, Orforglipron by Eli Lilly is the first oral (pill) GLP-1 receptor agonist. It achieves similar weight loss to Ozempic (~14.7% vs ~14.9%) but is taken as a daily pill instead of a weekly injection. It is currently in Phase 3 clinical trials and could be available by 2027.

Complete 2026 Guide — 9 Medications Compared

Every Weight Loss Peptide
Compared Head-to-Head (2026)

Q: What new weight loss drugs are coming in 2026-2027?

Several next-generation weight loss drugs are in late-stage trials: Retatrutide (triple agonist, 28.3% loss), CagriSema (amylin+GLP-1 combo, 22.7% loss), Survodutide (dual GLP-1/glucagon, 18.7% loss), Orforglipron (first oral GLP-1 pill, 14.7% loss), and Pemvidutide (dual agonist with liver benefits, 15.6% loss).

From FDA-approved Ozempic and Mounjaro to next-gen retatrutide, CagriSema, and the first oral GLP-1 pill. Clinical trial data, mechanisms, and expected results — all in one place.

The Complete Comparison Table

Drug	Mechanism	Avg Loss	Route	Status
Ozempic (Semaglutide)	GLP-1	14.9%	Weekly injection	FDA Approved
Wegovy (Semaglutide 2.4mg)	GLP-1	14.9%	Weekly injection	FDA Approved
Mounjaro (Tirzepatide)	GLP-1 + GIP	22.5%	Weekly injection	FDA Approved
Zepbound (Tirzepatide)	GLP-1 + GIP	20.9%	Weekly injection	FDA Approved
Retatrutide	GLP-1 + GIP + Glucagon	28.3%	Weekly injection	Phase 3 Complete
CagriSema	Amylin + GLP-1	22.7%	Weekly injection(s)	Phase 3 Complete
Survodutide	GLP-1 + Glucagon	18.7%	Weekly injection	Phase 3
Orforglipron	GLP-1 (oral)	14.7%	Daily PILL	Phase 3
Pemvidutide	GLP-1 + Glucagon	15.6%	Weekly injection	Phase 2b

Preview Your Transformation on Any Peptide

Upload a photo, choose your medication and timeline, and see what your body could look like.

FDA-Approved Medications (Available Now)

Ozempic / Wegovy

Semaglutide by Novo Nordisk. The original GLP-1 blockbuster.

Average loss: 14.9% (STEP-1)
Mechanism: GLP-1 only
Weekly injection

Preview Ozempic Results →

Mounjaro / Zepbound

Tirzepatide by Eli Lilly. Dual-agonist, more effective than semaglutide.

Average loss: 22.5% (SURMOUNT-1)
Mechanism: GLP-1 + GIP
Weekly injection

Preview Mounjaro Results →

Next-Generation Peptides (Coming 2026-2027)

These medications are in late-stage clinical trials and may receive FDA approval in the next 1-2 years. Their clinical data is already available.

Retatrutide

Triple agonist by Eli Lilly. The most powerful weight loss drug ever tested.

Average loss: 28.3% (TRIUMPH-1)
Max: 30.3% at 104 weeks
Mechanism: GLP-1 + GIP + Glucagon

Preview Retatrutide Results →

CagriSema

Amylin + GLP-1 combination by Novo Nordisk. Wegovy's successor.

Average loss: 22.7% (REDEFINE-1)
Mechanism: Amylin + GLP-1
Weekly injection(s)

Preview CagriSema Results →

Survodutide

Dual agonist by Boehringer Ingelheim. Strong liver fat reduction.

Average loss: 18.7% (SYNCHRONIZE-1)
Mechanism: GLP-1 + Glucagon
Weekly injection

Preview Survodutide Results →

Orforglipron

First oral GLP-1 PILL by Eli Lilly. No injections needed.

Average loss: 14.7% (ACHIEVE-1)
Mechanism: Oral GLP-1
Daily pill (no injection!)

Preview Orforglipron Results →

Pemvidutide

Dual agonist by Altimmune. Preserves lean mass, reduces liver fat.

Average loss: 15.6% (MOMENTUM)
Mechanism: GLP-1 + Glucagon
Weekly injection

Preview Pemvidutide Results →

Weight Loss Peptides Ranked by Effectiveness

#1
Retatrutide(28.3%)
Triple agonist — approaching bariatric surgery results
#2
CagriSema(22.7%)
Amylin + GLP-1 combination — Wegovy's next evolution
#3
Mounjaro/Zepbound(22.5%)
Best FDA-approved option (dual GIP/GLP-1)
#4
Survodutide(18.7%)
Dual GLP-1/glucagon with liver benefits
#5
Pemvidutide(15.6%)
Dual agonist, preserves lean mass
#6
Ozempic/Wegovy(14.9%)
The gold standard GLP-1 (most prescribed)
#7
Orforglipron(14.7%)
First oral GLP-1 pill — no injections

Frequently Asked Questions

What is the most effective weight loss peptide?

Based on clinical trial data, retatrutide is the most effective weight loss peptide ever tested, achieving 28.3% average body weight loss in the TRIUMPH-1 trial. However, it is not yet FDA-approved. Among approved medications, tirzepatide (Mounjaro/Zepbound) is the most effective at 22.5%.

Is there an oral weight loss pill like Ozempic?

Yes. Orforglipron by Eli Lilly is the first oral non-peptide GLP-1 agonist — a daily pill that achieves similar weight loss to Ozempic (~14.7%) without any injections. It is currently in Phase 3 trials.

What new weight loss drugs are coming in 2026-2027?

Several next-gen drugs are in late-stage trials: Retatrutide (28.3% loss), CagriSema (22.7%), Survodutide (18.7%), and Orforglipron (14.7% — first oral pill).

Is Mounjaro better than Ozempic?

Yes, clinical data consistently shows Mounjaro (tirzepatide) produces ~50% more weight loss than Ozempic (semaglutide): 22.5% vs 14.9%. Tirzepatide targets two hormonal pathways (GLP-1 + GIP) compared to semaglutide's single (GLP-1).

Preview Your Results on Any Medication

Upload your photo, choose any GLP-1 or peptide medication, set your timeline, and see your AI-powered transformation preview.

Individual Drug Guides

Medical Disclaimer: BeforeAfterFit is a visualization and motivation tool only. It does not provide medical advice. Several medications listed here are not yet FDA-approved. Clinical trial results represent population averages and may not reflect individual outcomes. Always consult your healthcare provider before starting any medication.